Bessemer Group Inc. Raises Position in Collegium Pharmaceutical, Inc. $COLL

Bessemer Group Inc. lifted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 48.0% in the first quarter, Holdings Channel reports. The firm owned 98,020 shares of the specialty pharmaceutical company’s stock after buying an additional 31,800 shares during the period. Bessemer Group Inc.’s holdings in Collegium Pharmaceutical were worth $3,241,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Collegium Pharmaceutical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 825 shares during the last quarter. Millennium Management LLC raised its stake in Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares in the last quarter. Jane Street Group LLC boosted its holdings in Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after acquiring an additional 90,255 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after acquiring an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.9%

Shares of COLL stock opened at $35.85 on Wednesday. The stock’s 50-day simple moving average is $34.61 and its 200-day simple moving average is $38.11. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The firm has a market capitalization of $1.16 billion, a PE ratio of 17.57 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a fifty-two week low of $29.19 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the previous year, the company posted $1.49 earnings per share. The company’s revenue was up 8.9% compared to the same quarter last year. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on COLL shares. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.